Payment overview · 2025
General Payments
$23,024.67
64 reported records · 18 companies
Healthcare provider profile · identity verified
Hani Shennib, MD
Allopathic & Osteopathic Physicians|Thoracic Surgery (Cardiothoracic Vascular Surgery) · MESA, AZ · NPI 1992801005
Verified facts
What the public records show
CMS Open Payments records show Hani Shennib, MD received $23,024.67 in general payments during 2025 across 64 reported records.
AngioDynamics, Inc. accounted for 90.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $20,716.78 | 90.0% | 14 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$662.42 | 2.9% | 13 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $351.76 | 1.5% | 4 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $234.60 | 1.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $229.54 | 1.0% | 2 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $208.16 | 0.9% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $148.72 | 0.7% | 5 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $131.49 | 0.6% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $83.36 | 0.4% | 4 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $65.47 | 0.3% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $35.56 | 0.1% | 2 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $30.39 | 0.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $29.05 | 0.1% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $24.89 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.53 | 0.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.20 | 0.1% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $17.51 | 0.1% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $16.24 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $18,583.33 | 1 |
| Food and Beverage | $3,098.17 | 58 |
| Travel and Lodging | $1,343.17 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $18,783.66 | 8 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $1,233.62 | 3 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $699.50 | 3 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $283.69 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $250.07 | 3 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $234.60 | 5 | 2025 |
Source payment records
|
|||||
| COOK Normalized: cook |
Device | Cook Medical LLC | $200.50 | 2 | 2025 |
Source payment records
|
|||||
| GORE TAG Thoracic Branch Endoprosthesis Normalized: gore tag thoracic branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $158.83 | 1 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $149.77 | 2 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $143.44 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $131.49 | 4 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $102.88 | 3 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $65.47 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $64.89 | 3 | 2025 |
Source payment records
|
|||||
| COMPLETE SE VASCULAR Normalized: complete se vascular |
Device | Medtronic, Inc. | $64.43 | 3 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $58.05 | 1 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $49.49 | 2 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $41.92 | 2 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $30.39 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| ABSOLUTE PRO Normalized: absolute pro |
Device | Abbott Laboratories | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| AMPHIRION DEEP Normalized: amphirion deep |
Device | Medtronic, Inc. | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| ADMIRAL XTREME Normalized: admiral xtreme |
Device | Medtronic, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $7.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 130 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
130 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
130 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 428 | 136 |
| Famotidine | Famotidine | 288 | 90 |
| Eliquis | Apixaban | 130 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 93 | 33 |
| Xarelto | Rivaroxaban | 89 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 81 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 18 |
| Lisinopril | Lisinopril | 72 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 31 |
| Furosemide | Furosemide | 60 | 22 |
| Losartan Potassium | Losartan Potassium | 41 | 13 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 17 |
| Prednisone | Prednisone | 26 | 11 |
| Bumetanide | Bumetanide | 25 | 11 |
| Omeprazole | Omeprazole | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Lorazepam | Lorazepam | 20 | 18 |
| Simvastatin | Simvastatin | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Gabapentin | Gabapentin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23,024.67 · 64 records | AngioDynamics, Inc. | ABRE, ABSOLUTE PRO, ADMIRAL XTREME, ALPHAVAC, AMPHIRION DEEP, ANGIOVAC, ARTEGRAFT VASCULAR GRAFT, AURYON LASER SYSTEM 100-120 VAC, Alto Abdominal Stent Graft System, CGuard Prime Carotid Stent System, CHOCOLATE PTA BALLOON CATHETER, COMPLETE SE VASCULAR, COOK, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK PERIPHERAL, ELIQUIS, ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent, EXCLUDER Conformable AAA Endoprosthesis with Active Control, FLOWTRIEVER CATHETER, S, GORE TAG Thoracic Branch Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, KEYTRUDA, LifeVest, MYNX CONTROL, PROTEGE RX, RotarexS 6 F x 135 cm, SUPERA, TREO ABDOMINAL STENT-GRAFT SYSTEM, Varithena Administration Pack, ZENITH SPIRAL-Z | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error